Pliant Therapeutics (PLRX) Operating Expenses (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Operating Expenses of $21.8 million for Q1 2026, down 63.06% year-over-year from $58.9 million in Q1 2025, and down 7.66% quarter-over-quarter from $23.6 million in Q4 2025.
Pliant Therapeutics (PLRX) Operating Expenses (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Operating Expenses for 8 consecutive years, with $21.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 63.06% year-over-year to $21.8 million; the TTM figure through Mar 2026 stood at $119.2 million (down 49.25% YoY), while the FY2025 annual figure was $156.4 million, down 31.52% from the prior year.
- Operating Expenses retreated to $21.8 million in Q1 2026 per PLRX's latest filing, from $23.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $62.0 million in Q3 2024 and bottomed at $21.8 million in Q1 2026.
- Historically, Operating Expenses has averaged $42.9 million across 5 years, with a median of $45.6 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 48.0% — and 2026, when it plunged 63.06%.
- Pliant Therapeutics' Operating Expenses stood at $39.4 million in 2022, then gained by 19.49% to $47.0 million in 2023, then grew by 13.36% to $53.3 million in 2024, then plunged by 55.78% to $23.6 million in 2025, then dropped by 7.66% to $21.8 million in 2026.
- Business Quant data shows PLRX's Operating Expenses at $21.8 million in Q1 2026, $23.6 million in Q4 2025, and $28.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | 23.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.86 Mn |
| Mar 31, 2026 | 21.77 Mn |
| Dec 31, 2025 | 23.58 Mn |
| Sep 30, 2025 | 28.27 Mn |
| Jun 30, 2025 | 45.59 Mn |
| Mar 31, 2025 | 58.94 Mn |
| Dec 31, 2024 | 53.32 Mn |
| Sep 30, 2024 | 62.01 Mn |
| Jun 30, 2024 | 60.64 Mn |
| Mar 31, 2024 | 52.39 Mn |
| Dec 31, 2023 | 47.04 Mn |
| Sep 30, 2023 | 47.69 Mn |
| Jun 30, 2023 | 47.58 Mn |
| Mar 31, 2023 | 43.43 Mn |
| Dec 31, 2022 | 39.37 Mn |
| Sep 30, 2022 | 33.43 Mn |
| Jun 30, 2022 | 34.63 Mn |
| Mar 31, 2022 | 29.46 Mn |
| Dec 31, 2021 | 26.60 Mn |
| Sep 30, 2021 | 28.72 Mn |